p38 MAPK inhibition safeguards genome integrity during gene editing of hematopoietic stem and progenitor cells.

Authors

Roberta Vacca, Lucrezia Della Volpe, Nicolò Gualandi, Kohei Shiroshita, Edoardo Carsana, Kety Giannetti, Chiara Gaddoni, Fabrizio Benedicenti, Barbara Gega, Sergio Arévalo, Parinaz Zarghamian, Stefano Beretta, Maria Carmina Castiello, Chiara Brombin, Daniele Canarutto, Ivan Merelli, Toni Cathomen, Eugenio Montini, Anna Villa, Luigi Naldini, Raffaella Di Micco

Published in

Molecular therapy : the journal of the American Society of Gene Therapy. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Ex vivo genome editing of hematopoietic stem and progenitor cells (HSPCs) holds significant therapeutic potential but remains constrained by genotoxic risks associated with nuclease-induced DNA double-strand breaks, DNA donor template delivery and sensing, and proliferation-induced stress during ex vivo manipulation. These processes can lead to chromosomal instability, large on-target deletions, donor mis-integration, off-target events, and impaired long-term stem cell function, raising safety concerns for clinical translation. Here, we evaluate the impact of transient p38 MAPK inhibition on genomic integrity during clinically relevant CRISPR-Cas9 editing and show that this intervention attenuates ex vivo culture-associated stress without increasing detectable genotoxic outcomes. Comprehensive genotoxicity analyses, including quantification of large on-target deletions, adeno-associated viral vector mis-integration, and CAST-seq mapping of translocations, reveal no measurable differences in gene editing-associated structural alterations upon p38 MAPK inhibition, while micronuclei were significantly reduced. Importantly, long-term xenotransplantation followed by whole-exome sequencing shows that p38i-treated HSPCs display a reduced mutational burden without evidence of increased genomic alterations. Collectively, these findings identify transient p38 MAPK inhibition as a strategy to improve the quality and long-term fitness of gene-edited HSPCs without detectable adverse effects on the genome editing outcomes, supporting its further evaluation as a refinement to clinically relevant CRISPR-Cas9 editing workflows.

PMID:
42768749
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.